CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
-6.97%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$718M
AUM Growth
+$718M
(-55%)
Cap. Flow
-$782M
Cap. Flow
% of AUM
-108.88%
Top 10 Holdings %
Top 10 Hldgs %
78.87%
Holding
35
New
4
Increased
1
Reduced
16
Closed
9
Top Buys
| 1 |
Icon
ICLR
|
$43.6M |
| 2 |
Merck
MRK
|
$39.6M |
| 3 |
UnitedHealth
UNH
|
$31.2M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$14.7M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$5.5M |
Top Sells
| 1 |
Zimmer Biomet
ZBH
|
$114M |
| 2 |
Humana
HUM
|
$104M |
| 3 |
Baxter International
BAX
|
$87.8M |
| 4 |
CVS Health
CVS
|
$82.8M |
| 5 |
PTC Therapeutics
PTCT
|
$76.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Zimmer Biomet
ZBH
$21B
| $91.2M | 8.56% | 1,000,000 -1,250,000 | -56% | -$114M |
|
|
2
Baxter International
BAX
$12.7B
| $86.3M | 8.1% | 2,850,000 -2,900,000 | -50% | -$87.8M |
|
|
3
Humana
HUM
$36.5B
| $73.3M | 6.89% | 300,000 -425,000 | -59% | -$104M |
|
|
4
CVS Health
CVS
$92.8B
| $72.4M | 6.8% | 1,050,000 -1,200,000 | -53% | -$82.8M |
|
5
Globus Medical
GMED
$8.27B
| $47.2M | 4.43% | 800,000 -450,000 | -36% | -$26.6M |
|
|
6
Icon
ICLR
$13.8B
| $43.6M | 4.1% | +300,000 | New | +$43.6M |
|
7
Ascendis Pharma
ASND
$11.8B
| $43.2M | 4.05% | 250,000 -100,000 | -29% | -$17.3M |
|
|
8
Merck
MRK
$210B
| $39.6M | 3.72% | +500,000 | New | +$39.6M |
|
9
Pfizer
PFE
$141B
| $36.4M | 3.41% | 1,500,000 -1,000,000 | -40% | -$24.2M |
|
|
10
BioMarin Pharmaceuticals
BMRN
$11.2B
| $33M | 3.1% | 600,000 +100,000 | +20% | +$5.5M |
|
|
11
UnitedHealth
UNH
$281B
| $31.2M | 2.93% | +100,000 | New | +$31.2M |
|
12
Viatris
VTRS
$12.3B
| $24.6M | 2.31% | 2,750,000 -4,750,000 | -63% | -$42.4M |
|
13
Brookdale Senior Living
BKD
$1.83B
| $15M | 1.4% | 2,150,000 -4,100,000 | -66% | -$28.5M |
|
14
ZimVie
ZIMV
$532M
| $15M | 1.4% | 1,600,000 -285,000 | -15% | -$2.66M |
|
|
15
Apellis Pharmaceuticals
APLS
$3.48B
| $14.7M | 1.38% | +850,000 | New | +$14.7M |
|
16
Myriad Genetics
MYGN
$593M
| $10.6M | 1% | 2,000,000 -350,000 | -15% | -$1.86M |
|
17
Evolent Health
EVH
$1.12B
| $9.57M | 0.9% | 850,000 -2,150,000 | -72% | -$24.2M |
|
|
CON
18
Concentra Group Holdings Parent, Inc.
CON
$3.05B
| $8.23M | 0.77% | 400,000 -1,200,000 | -75% | -$24.7M |
|
19
Inogen
INGN
$216M
| $6.85M | 0.64% | 975,000 | – | – |
|
20
Denali Therapeutics
DNLI
$2.23B
| $5.6M | 0.53% | 400,000 -850,000 | -68% | -$11.9M |
|
21
Theravance Biopharma
TBPH
$699M
| $4.96M | 0.47% | 450,000 -550,000 | -55% | -$6.07M |
|
22
AnaptysBio
ANAB
$569M
| $2.78M | 0.26% | 125,000 -625,000 | -83% | -$13.9M |
|
23
OraSure Technologies
OSUR
$242M
| $2.7M | 0.25% | 900,000 | – | – |
|
24
Cigna
CI
$80.3B
| – | – | -200,000 | Closed | -$65.8M |
|
25
Genmab
GMAB
$15.3B
| – | – | -50,000 | Closed | -$979K |
|